Iraqi Postgraduate Medical Journal

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

Copyrights and Licensing

Home

About Journal

Aim and Scope

Editorial Board

Peer Review Process

Copyrights and Licensing

Indexing and Abstracting

Plagiarism Policy

Author's Guide

Article processing charge (APC)

The effects of body mass index on serum prostatic specific antigen level in correlation to age and prostatic size

,

Document Type : Research Paper

Abstract

Abstract
Background: Prostatic Specific Antigen (PSA) is considered the most dependent tumor marker of carcinoma of prostate. It is considering organ-specific tumor marker but not disease specific. It is the most prevalent screening tool for carcinoma of prostate and most proportion of prostatic carcinoma are diagnosed with prostatic biopsy when there is abnormally elevated level of serum PSA.
Aim of study: Our research study aimed to define the relationship of BMI (body mass index ) as a marker of obesity with serum PSA level and their correlation to age and prostatic volume.
Patients and methods: Our study involved 115 cases with their age was more than 55 years. In 35 cases, their age was between 55 and 59 years, in 53 cases their age was between 60 to 69 years, and in 27 cases, the age was above 70 years. Their BMI categorized into 3 groups: group 1 include obese people (BMI > 27kg/m2) which includes 55 cases, group 2 overweights (BMI 23- 27 kg/m2) which include 37 cases, and group 3 includes normal weights (BMI 18.5 - 23kg/m2) which include 23 cases. Body mass index, total serum PSA and volume of prostate were measured for every case in this research and the results are analyzed statistically by using IBM-SPSS 26. A P-value ≤ 0.05 deemed significant for this study.
Results: Obese individuals exhibited significantly lower median serum PSA in comparison to overweight and normal BMI males 1.6, 2.2, 2.69 ng/ml, in group 1, group 2, and group 3 respectively. There is a considerable significantly negative correlation of PSA with BMI (Spearman’s coefficient= -0396, p=0.001). Also, there was no statistically significant variation found between the groups regarding prostate size (p = 0.532). There was a positive correlation of serum PSA with the age (r= 203, p = 0.029).

Keywords

Main Subjects

References
  1. Jenan Akbar Shakoor, Abbas Lateef Muhe Al-deen. Prevalence of obesity and overweight among public primary school students in kirkuk city. Journal of Natural Sciences Research, 2015;5:59-66.
  2. Laaksonen DE, Laukkanen JA, Niskanen L, Nyyssönen K, Rissanen TH, Voutilainen S, Pukkala E, Hakkarainen A, Salonen JT. Serum linoleic and total polyunsaturated fatty acids in relation to prostate and other cancers: A population‐ based cohort study. International journal of cancer, 2004;111:444-50.
  3. Parikh NI, Pencina MJ, Wang TJ, Lanier KJ, Fox CS, D’Agostino RB, Vasan RS. Increasing trends in incidence of overweight and obesity over 5 decades. The American journal of medicine, 2007;120:242-50.
  4. Shah NR, Braverman ER. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PloS one, 2012;7: e33308.
  5. Mohammed Ali khalaf, Bilal Jamal Kamal, Assad Mubark. Prevalence of obesity among kirkuk university personnel's. Neuro Quantology, 2022;20:1251-59.
  6. Chiu PK, Wong AY, Hou SM, Yip SK, Ng CF. Effect of body mass index on serum prostate-specific antigen levels among patients presenting with lower urinary tract symptoms. Asian Pac J Cancer Prev, 2011;12:1937-40.
  7. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health, 2011;9:88.
  8. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC, Kane CJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Jama, 2007;298:2275-80.
  9. M Mohammed M, Khalid Abdulridha M, Mustafa Kamal Al Y. Body Mass Index (BMI), lipid profile, leptin level and their correlation with Prostate Specific Antigen (PSA) in Iraqi patients with Benign Prostatic Hyperplasia (BPH). Karbala journal of pharmaceutical sciences, 2013;4:18-31.
  10. Helal NN. The Effect of Body Mass Index and Serum Estradiol on Serum Prostatic Specific Antigen in Normal Iraqi Men. Al-Anbar Medical Journal, 2010;8:7-13.

 

  1. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen- deprivation therapy. Journal of clinical oncology, 2006;24:3979-83.
  2. Arab D, Zadeh AA, Mirmohammadkhani M, Beiglarzadeh A. Prostate-specific antigen rising in Iranian men in correlation with body mass index, fasting blood sugar and blood lipid profile. Journal of nephropathology, 2016;5:134-38.
  3. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: implications in carcinogenesis. Trends in Endocrinology & Metabolism, 2000;11:54-60.
  4. Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodríguez JA, Ortiz-Sánchez E, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC cancer, 2013;13:1-3.
  5. Mejak SL, Bayliss J, Hanks SD. Long distance bicycle riding causes prostate- specific antigen to increase in men aged 50 years and over. PLoS One, 2013;8:1-6:
  6. Park SC, Shin YS, Zhang LT, Kim DS, Kim SZ, Park NC, Ahn TY, Kim JJ, Lee SW, So I, Park JK. Prospective investigation of change in the prostate-specific antigens after various urologic procedures. Clinical interventions in aging, 2015;10:1213-18.
  7. Kaplan SA, Lee RK, Chung DE, Te AE, Scherr DS, Tewari A, Vaughan ED. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer. The Journal of urology, 2012;188:757-61.
  8. Burton AJ, Martin RM, Donovan JL, Lane JA, Davis M, Hamdy FC, Neal DE, Tilling K Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. Cancer Epidemiol Biomark Prev, 2012;21:1877–85.
  9. National Institute for Health and Care Excellence guidelines for suspected cancer: recognition and referral. NICE guideline. Published: 23 June 2015. Last updated: 2 October 2023. Part 1.6.1. Available online on: https://www.nice.org.uk/guidance/ng12/resources/suspected-cancer-recognition-and-referral-pdf-1837268071621. Accessed on 7 Nov 2023.
  10. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ. Prevalence of prostate cancer among men with a prostate-specific antigen level≤ 4.0 ng per milliliter. New England Journal of Medicine, 2004;350:2239-46.
  11. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiologic reviews, 2007;29:88-97.
  12. Freedland SJ, Platz EA, Presti JC, Aronson WJ, Amling CL, Kane CJ, Terris MK. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. The Journal of urology, 2006;175:500-4.
  13. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC, Kane CJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Jama, 2007;298:2275-80.
  14. Harrison S, Tilling K, Turner EL, Lane JA, Simpkin A, Davis M, Donovan J, Hamdy FC, Neal DE, Martin RM. Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?. Cancer Causes & Control, 2016;27:1465-74.
  15. Farhan SD. The Effect of Body Mass Index and Waist Circumference on Prostate Specific Antigen in Patients with Benign Prostatic Hyperplasia (BPH). Iraqi journal of medical sciences, 2011;9:34-40.
  16. Liu M, Wang JY, Zhu L, Wan G. Body mass index and serum lipid profile influence serum prostate-specific antigen in Chinese men younger than 50 years of age. Asian journal of andrology, 2011;13:640-43.
  17. Pater LE, Hart KW, Blonigen BJ, Lindsell CJ, Barrett WL. ‘Relationship between prostate-specific antigen, age and body mass index in a prostate cancer screening population. American journal of clinical oncology, 2012;35:490-92.
  18. Yue L, Ge Y, Wang T, Ge M, Zhang C, Zhang W. The correlation between body mass index and prostatic-related parameters in men 40 years or older in Zhengzhou. The Aging Male, 2020; 23:483-88.
  19. Beebe‐Dimmer JL, Faerber GJ, Morgenstern H, Werny D, Wojno K, Halstead‐ Nussloch B, et al. Body composition and serum prostate‐specific antigen: review and findings from Flint Men's Health Study. Urology, 2008;71:554-60.
  20. Lee SH, Kim JC, Lee JY, Kim JH, Oh CY, Lee SW et al. Effect of obesity on lower urinary tract symptoms in Korean benign prostate hyperplasia patients. Asian journal androl, 2009;11:663-68.

 

Iraqi Postgraduate Medical Journal
Volume 24, Issue 1
January 2025
Page 114-121
Files
Share
Export Citation
Statistics